Guidelines for the diagnosis and treatment of acromegaly: A Canadian perspective

Clinical and Investigative Medicine

Volumn 23, Issue 3, 2000, Pages 172-187

  Patel, Yogesh C ^a,h   Ezzat, Shereen ^b   Chik, Constance L ^c   Rorstad, Otto P ^d   Serri, Omar ^e   Ur, Ehud ^f   Wilkins, G Edward ^g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PEGVISOMAT; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; ARTHROPATHY; CLINICAL TRIAL; COLON TUMOR; DIABETES MELLITUS; ECTOPIC HORMONE PRODUCTION; HEART DISEASE; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOPHYSIS FUNCTION; META ANALYSIS; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME;

ACROMEGALY; CANADA; HEALTH CARE COSTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PITUITARY GLAND; PRACTICE GUIDELINES; RADIOTHERAPY; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 0033858685     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. 1. Melmed S. Acromegaly. N Engl J Med 1990;322:966-77.
2. 2. Wass JA. Acromegaly. Treatment after 100 years. BMJ 1993;307:1505-6.
3. 3. Barkan AL. Acromegaly: diagnosis and therapy. Endocrinol Metab Clin North Am 1989;18:277-310.
4. 4. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21:597-614.
5. 5. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-402.
6. 6. Ezzat S, Wilkins GE, Patel YC, Ur E, Rorstad O, Serri O. The diagnosis and management of acromegaly: a Canadian consensus report. Clin Invest Med 1996;19:259-70.
7. 7. Drange MR, Melmed S. Molecular pathogenesis of acromegaly. Pituitary 1999;2:43-50.
8. 8. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41.
9. 9. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646-52.
10. 10. Chapman IM, Hartman ML, Strane M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower post-glucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994;78:1312-7.
11. 11. Ivanmanesh A, Grisso B, Veldhuis JD. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1994;78:526-35.
12. 12. Frogsted AK, Halsa J, Bakka S. Sandostatin-LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997;82:23-8.
13. 13. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80(11): 3267-72.
14. 14. Priou A, Levesque G, Simonetta C, Lancranjan I, Roger P, Jacquet P. [Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly.] Ann Endocrinol (Paris) 1995;56(3):213-8.
15. 15. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45(8 Suppl 1)5:67-71.
16. 16. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly [review]. Drugs 1997;53(4):681-99.
17. 17. Lamberts SW, van der Lely AJ, de Herder WW. Octreotide [review]. N Engl J Med 1996;334(4):246-54.
18. 18. Colao A, Ferone D, Marzullo P, Di Samo A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82(2):518-23.
19. 19. Abs R, Verhelst J, Mailer D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study of 64 patients. J Clin Endocrinol Metab 1998;83:374-8.
20. 20. Cozzi R, Attanasio R, Barausse M, Dallabonanza D, Orlandi P, Da Re N, et al. Eur J Endocrinol 1998;139: 516-21.
21. 21. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-7.
22. 22. Jackson IM, Noren G. Role of gamma knife radio-surgery in acromegaly. Pituitary 1999;2:71-7.
23. 23. Jaffe CA. Reevaluation of conventional pituitary irradiation in the therapy of acromegaly. Pituitary 1999;2:55-62.
24. 24. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human [review]. Endocr Rev 1998;19(6):717-97.
25. 25. Patel YC. Neurotransmitters and hypothalamic control of anterior pituitary function. In: DeGroot LJ, Jameson, JL, Burger H, et al, editors. Endocrinology. 4th ed. Philadelphia: W.B. Saunders; 2001 (in press).
26. 26. Patel YC. Somatostatin and its receptor family [review]. Front Neuroendocrinol 1999;20(3):157-98.
27. 27. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1997;56(5):333-42.
28. 28. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors [review]. N Engl J Med 1997;336(9):633-40.
29. 29. Sjogren K, Liu JL, Blad K, Skrtic S, Vidai O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999;96(12):7088-92.
30. 30. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301(21):1138-42.
31. 31. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83(110): 3808-16.
32. 32. Irie M, Tsushima T. Increase of serum growth hormone concentration following thyrotropin releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab 1972;35:97-100.
33. 33. Wright AD, Hill DM, Lowry C, Fraser TR. Mortality in acromegaly. Q J Med 1970;39(153):1-16.
34. 34. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41 (1):95-102.
35. 35. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86(5):293-9.
36. 36. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study .United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8): 2730-4.
37. 37. Serri O, Somma M, Comtois R, Rasio E, Beauregard H, Jilwan N, et al. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 1985;61(6):1185-9.
38. 38. Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988; 68(6):854-67.
39. 39. Tindall GT, Oyesiku MM, Watts NB, Clerk RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 1993;78(2):205-15.
40. 40. Fahlbusch R, Honegger J, Schott W, Buckfelder M. Results of surgery in acromegaly. In: Wass JA, editor. Treating acromegaly. J Endocrinol 1994;[special issue]:49-54.
41. 41. Lawson ER Jr, Carpenter SM, Scheithauer BW, Randall RV. Long-term results of transsphenoidal surgery for the management of acromegaly. In: Robbins R, Melmed S, editors. Acromegaly: a century of scientific and clinical progress, New York: Plenum Press; 1987. p. 241-8..
42. 42. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83(10):3411-8.
43. 43. Swearingen B, Barker FG 2d, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83(10): 3419-26.
44. 44. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89(3):353-8.
45. 45. Truong U, Hardy J, Serri O. Evaluation of biochemical cure after long-term foJlow-up of 59 acromegalic patients who underwent transsphenoidal microsurgery [abstract]. Annual meeting of the US. Endocrine Society, San Diego, June 1999. abstr 651.
46. 46. Reubi JC, Landolt AM. The growth hormone response to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989;68(4):844-50.
47. 47. Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson LA, et al. Molecular biology of somatostatin receptor subtypes [review]. Metabolism 1996;45 (8 Suppl 1):31-8.
48. 48. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31(11):1133-40.
49. 49. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 1996;81(6):2089-97.
50. 50. Caron P, Morange-Ramos I, Cogre M, Jacquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82(1):18-22.
51. 51. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 1990;71(2):391-7.
52. 52. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117(9):711-8.
53. 53. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83(9):3034-40.
54. 54. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67(5):1040-8.
55. 55. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe H. Preoperative Octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79(5):1416-23.
56. 56. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82(10): 3308-14.
57. 57. Besser GM, Wass JA. Medical management of acromegaly with bromocriptine. Effects of continuous treatment for over three years. Med J Aust 1978;2(3 Suppl):31-3.
58. 58. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists [review]. Endocrinol Metab Clin North Am 1992;21(3):713-35.
59. 59. Halse J, Harris AG, Kvistborg A, Kjartansson O, Hanssen E, Smiseth O, et al. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab 1990;70(5):1254-61.
60. 60. Pelkonen R, Ylikahri R, Koronen SL. Bromocriptine treatment of patients with acromegaly resistant to conventional therapy. Clin Endocrinol (Oxf) 1980;12(3): 219-24.
61. 61. Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994;79(2):461-5.
62. 62. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288:154-7.
63. 63. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy resistant acromegalic patients. Pituitary 1999; 1:115-20.
64. 64. Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 1979;48(6):931-40.
65. 65. Goffman TE, Dewan R, Arakaki R, Corden P, Oldfield EH, Glatstein E. Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safety of post-surgical radiation therapy. Cancer 1992; 69(1):271-5.
66. 66. Speirs CJ, Reed PI, Morrison R, Aber V, Joplin GF. The effectiveness of external brain radiotherapy for acromegaly is not affected by previous pituitary ablative treatments. Acta Endocrinol (Copenh) 1990; 122(5): 559-65.
67. 67. Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, Padfield PL, et al. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors? Clin Endocrinol 1984;20(4):401-8.
68. 68. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82(10):3187-91.
69. 69. Simmons NE, Law ER Jr. Glioma occurrence after sellar irradiation: case report and review. Neurosurgery 1998;42:172-8.
70. 70. Wilson LS, Shin JL, Ezzat S. Costs analysis of different therapeutic options in the management of acromegaly [abstract]. Annual meeting of the US Endocrine Society, San Diego, June 1999; abstr OR24-5.
71. 71. Newman CB. Medical therapies for acromegaly. Endocrinol Metab Clin North Am 1999;28:171-90.
72. 72. Chanson P. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? Eur J Endocrinol 1994;136(4):359-61.
73. 73. Clayton RN, Stewart PM, Shalet SM, Wass JA. Pituitary surgery for acromegaly. Should be done by specialists. BMJ 1999;319(7210):588-9.
74. 74. Weekes LM, Ho KK, Scale JP. Treatment options in acromegaly. Benefits and costs [review]. Pharmacoeconomics 1996;10(5):453-9.
75. 75. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100(9):2386-2392.